Congress ought to “state clearly” that hemp-derived THC and other intoxicating cannabinoids extracted from hemp are subject to the Controlled Substances Act (CSA), according to a new report sponsored by federal health authorities.
States should also follow “product quality and analytical standards” for cannabis flower and extracts set by the U.S. Pharmacopeia rather than conflicted regulations impacted by marijuana industry lobbying, according to a National Academies of Science, Engineering, Medicine report released Thursday, “Cannabis Policy Impacts Health and Health Equity.”
ADVERTISEMENT
According to its website, the U.S. Pharmacopeia is an “independent, scientific nonprofit organization focused on building trust in the supply of safe, quality medicines.”
States prioritized ‘financial interests’ of cannabis
The “Cannabis Policy Impacts Health and Health Equity” report took a wide-ranging
Read full article on Marijuana Business Daily
